Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia

Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia

Abstract Background Acute myeloid leukemia (AML) is the most common type of adult leukemia. Several studies have demonstrated that oncogenesis in AML is enhanced by kinase signaling pathways such as Src family kinases (SFK) including Src and Lyn, spleen tyrosine kinase (SYK), and bruton’s tyrosine k...

Full description

Bibliographic Details
Main Authors: Ola A. Elgamal, Abeera Mehmood, Jae Yoon Jeon, Bridget Carmichael, Amy Lehman, Shelley J. Orwick, Jean Truxall, Virginia M. Goettl, Ronni Wasmuth, Minh Tran, Shaneice Mitchell, Rosa Lapalombella, Sudharshan Eathiraj, Brian Schwartz, Kimberly Stegmaier, Sharyn D. Baker, Erin Hertlein, John C. Byrd
Format: Article
Language:English
Published: BMC 2020-01-01
Series:Journal of Hematology & Oncology
Subjects:
Acute myeloid leukemia
Multi-kinase inhibitor
ArQule 531
Online Access:https://doi.org/10.1186/s13045-019-0821-7

Internet

https://doi.org/10.1186/s13045-019-0821-7

Similar Items